Organization (Industry)
GE Healthcare (Hungary)
ClinicalTrials.gov lists GE Healthcare (Hungary) as lead sponsor of 174 trials. It has 25 active development programs and 25 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 18 registered with a 2026 start date. The hollow diamonds on the dashed line are a forecast of the full-year count, planned starts included: about 19 in 2026 and about 17 in 2027, the average of the 24 months through September, counted as registered and carried forward. The columns, the lighter one included, count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. This method has not been backtested on organizations. In backtests on conditions with as many trial starts a year as this organization (5 to 20), forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.
Logo GE HealthCare/Interbrand (design firm), via Wikimedia Commons, Public domain. Shown to identify the organization; it may be a registered trademark.
This page covers GE Healthcare (Hungary): 174 lead-sponsored trials and 5 legal-entity registrations.
Disease areas (162)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Breast Neoplasms | 38 |
| Coronary Disease | 33 |
| Coronary Artery Disease | 31 |
| Dementia | 14 |
| Heart Failure | 14 |
Showing 5 of 162 disease areas.
Trials by start year as sponsor or collaborator (26)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 18 |
| 2025 | 18 |
| 2024 | 13 |
| 2023 | 14 |
| 2022 | 13 |
| 2021 | 13 |
| 2020 | 7 |
| 2019 | 6 |
| 2018 | 19 |
| 2017 | 21 |
Showing 10 of 26 years.
Prediction, not a registry value: median of 25 months from start to primary completion across 7 trials still running at the 2026-10-09 snapshot; 2 of 7 predicted trials reach the 36-month horizon; registered median of 12 months across 137 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (25)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| SPECT MPI | Coronary Artery Disease | Phase 3 | 1 |
| SPECT MPI | Coronary Disease | Phase 3 | 1 |
| Pharmacological stress agents | Coronary Artery Disease | Phase 3 | 1 |
| Pharmacological stress agents | Coronary Disease | Phase 3 | 1 |
| PET | Parkinson Disease | Phase 3 | 1 |
Showing 5 of 25 active programs.
Approved assets (25)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Iodixanol | 7 |
| 123I-mIBG (meta-iodobenzylguanidine) | 4 |
| DEFINITY | 3 |
| 18F Fluoroestradiol Radiopharmaceutical with PET/CT | 2 |
| Hexaminolevulinate (HAL) | 2 |
Showing 5 of 25 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 35% hit target (n=43) | 24% on time (n=38) |
Journals published in (186)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Journal of the American College of Cardiology | 25 |
| Radiology | 22 |
| AJR. American journal of roentgenology | 18 |
| Circulation | 14 |
| The New England journal of medicine | 13 |
Showing 5 of 186 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 307 | 20 | 2025-09-30 |
SEC-reported annual financials (6)
Shown in this order: newest fiscal year first; SEC EDGAR XBRL companyfacts, USD as reported.
| Fiscal year | Revenue (USD) | Net income (USD) | R&D (USD) |
|---|---|---|---|
| 2025 | 20,625,000,000 | 2,084,000,000 | 1,260,000,000 |
| 2024 | 19,672,000,000 | 1,993,000,000 | 1,311,000,000 |
| 2023 | 19,552,000,000 | 1,568,000,000 | 1,205,000,000 |
| 2022 | 18,341,000,000 | 1,916,000,000 | 1,026,000,000 |
| 2021 | 17,585,000,000 | 2,247,000,000 | 816,000,000 |
| 2020 | not reported | not reported | not reported |
Financing and grant events (42)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2026-02-26 | Debt financing | not disclosed | Sec extracted |
| 2025-12-15 | Debt financing | 1,250,000,000 | Sec extracted |
| 2025-12-12 | Debt financing | not disclosed | Sec extracted |
| 2025-12-02 | Debt financing | 1,245,144,500 | Edgar offerings |
| 2025-12-01 | Other financing | not disclosed | Edgar offerings |
Showing 5 of 42 events.
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| NAI | 12 |
FDA import refusals (1)
| Refused import lines | Latest refusal |
|---|---|
| 1 | 2025-05-23 |
Manufacturing and distribution sites (14)
Shown in this order: severity rank then name.
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| GE Healthcare (Shanghai) Co Ltd. | China (Shanghai) Pilot Free Trade Zone, CN | EMA, FDA, Health Canada | GE Healthcare (Shanghai) Co Ltd. |
| GE HEALTHCARE | Chicago, US | FDA | |
| GE Healthcare AS | Oslo, NO | EMA, FDA, Health Canada | GE Healthcare AS |
| GE Healthcare AS | Oslo, NO | EMA | GE Healthcare AS |
| GE Healthcare B.V. | Zwolle, NL | EMA | GE Healthcare B.V. |
Showing 5 of 14 sites.
Climate targets, as filed (1)
| Reporting year | Net-zero target |
|---|---|
| 2025 | not disclosed |
Workforce and board diversity, as filed (1)
| Reporting year | Workforce % women | Board % women |
|---|---|---|
| 2025 | not disclosed | not disclosed |
Organization relationships (80)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Government of the United States of America | Co sponsors trial with | 7 |
| Iqvia Holdings Inc. | Uses vendor | 7 |
| i3 Statprobe | Co sponsors trial with | 7 |
| Medpace Holdings, Inc. | Uses vendor | 6 |
| Icon Plc | Uses vendor | 5 |
Showing 5 of 80 relationships.
Latest dated events (699)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-10 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-10 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-10 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-09-15 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-09-15 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 699 events.
Biomarker capability evidence (227)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ACE | Trial sponsor | Named in trial inclusion criteria |
| ALB | Trial collaborator | Named in trial inclusion criteria |
| ALB | Trial collaborator | Named in trial inclusion criteria |
| ALB | Trial collaborator | Named in trial inclusion criteria |
| APOE | Trial collaborator | Named in trial inclusion criteria |
Showing 5 of 227 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, fda warning letters, fda untitled letters, fda recalls, clia clinical laboratory certificates, and biomarkers this organization publishes on.